Obermatt
See Similar Stocks →

JW

KSC:096760 · KR7096760004
PharmaceuticalsSmall

360

97
Medium confidence — indicative
Profit price35
Owner Earnings Yield93
Dividend Yield1
Price/Sales87
EV / Gross Profit91
Price/Book47
Return on Capital97
Cash Return on Capital89
Return on Equity94
EBIT Margin95
Gross Profitability86
Cash Conversion89
Accruals51
Owner Earnings Margin85
Sales growth29
Profit Growth61
Long-Term EPS Growth38
Owner Earnings Growth67
Reinvestment20
Price momentum73
Debt load23
Refinancing70
Debt Payback27
Liquidity57
Analyst ratings—
Expectations trend—
Market mood43
Value Creation18/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

JW generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeKOSE
Employees17
Websitejw-holdings.co.kr
ISINKR7096760004
Last UpdateApr 2, 2026
Indices
KOSPI (South Korea)
Themes
LifestyleReproductive HealthNutraceuticalWomen's HealthHealth DiagnosticsPain ManagementHealth CareMedicalService Industry

Description

Analysis

Hidden champion

JW Holdings Corporation fits the profile of a hidden champion, yet the market has not awarded it the premium its quality earns.

On valuation, the picture is attractive. The owner-earnings multiple stands at 2.9×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is adequate. The company scores 18/20 on our value-creation score: strong value creator.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
38
20232026

All-time high

45

Mar 2026

All-time low

13

Jan 2023

Average rank

32

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
87
—
—
98
Price/Earnings
100
—
—
6
Price/Book
47
—
—
28
Dividend Yield
1
—
—
85
Value (overall)
67
—
—
55

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare JW with its peers
JW Pharmaceutical
KSC:001060
95
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Samsung Pharm
KSC:001360
—
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Kwangdong Pharmaceutical
KSC:009290
80
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Kukje Pharma
KSC:002720
43
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Jeil Pharma
KSC:002620
73
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Ildong Holdings
KSC:000230
83
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →